Eli Lilly weekly recap highlights Q2 strength, FDA approval

Recap says Eli Lilly surged on strong Q2 results and raised guidance, citing growth drivers including Mounjaro, Zepbound and oral Foundayo, plus advances from Inluriyo, Retatrutide, Foundayo and CAR—T/vaccine investments. It also mentions pricing moves and legal risks reshaping the outlook and references FDA approval for Inluriyo and Verzenio.